îāļāđāļāļŦāļē
îž
î
āļĨāđāļāļāļāļīāļ
îāļāđāļāļŦāļē
î
Pfizer Inc
PFEîāđāļāļīāđāļĄāļĨāļāđāļāļĢāļēāļĒāļāļēāļĢāļāļīāļāļāļēāļĄ
25.900USD
-0.050-0.19%
āļāļīāļÂ 05/22, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
147.27BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
19.67P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Pfizer Inc āļāļĢāļīāļĐāļąāļ
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
āļāđāļāļĄāļđāļĨ Pfizer Inc
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPFE
āļāļ·āđāļāļāļĢāļīāļĐāļąāļPfizer Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 22, 2080
āļāļĩāļāļĩāđāļBourla (Albert)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ81000
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 22
āļāļĩāđāļāļĒāļđāđ66 Hudson Boulevard East
āđāļĄāļ·āļāļNEW YORK
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ10001-2192
āđāļāļĢāļĻāļąāļāļāđ12127332323
āđāļ§āđāļāđāļāļāđhttps://www.pfizer.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPFE
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 22, 2080
āļāļĩāļāļĩāđāļBourla (Albert)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Pfizer Inc
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
394.63K
+4.08%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7.61%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
68.47K
-3.36%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
32.73K
+5.39%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
--
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
26.59K
+6.54%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
394.63K
+4.08%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7.61%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
68.47K
-3.36%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
32.73K
+5.39%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 6 āđāļĄ.āļĒ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 6 āđāļĄ.āļĒ.
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Eliquis alliance revenues and direct sales
7.96B
12.72%
Prevnar family
6.49B
10.38%
Vyndaqel family
6.38B
10.20%
Comirnaty
4.37B
6.98%
Oncology-Ibrance
4.12B
6.59%
āļāļ·āđāļ āđ
33.26B
53.14%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
United States
37.08B
59.25%
Developed Markets
16.19B
25.87%
Emerging Markets
9.31B
14.88%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Eliquis alliance revenues and direct sales
7.96B
12.72%
Prevnar family
6.49B
10.38%
Vyndaqel family
6.38B
10.20%
Comirnaty
4.37B
6.98%
Oncology-Ibrance
4.12B
6.59%
āļāļ·āđāļ āđ
33.26B
53.14%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 10 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 10 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Vanguard Capital Management, LLC
6.48%
State Street Investment Management (US)
5.27%
BlackRock Institutional Trust Company, N.A.
5.22%
Geode Capital Management, L.L.C.
2.28%
Vanguard Portfolio Management, LLC
2.05%
āļāļ·āđāļ āđ
78.70%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Vanguard Capital Management, LLC
6.48%
State Street Investment Management (US)
5.27%
BlackRock Institutional Trust Company, N.A.
5.22%
Geode Capital Management, L.L.C.
2.28%
Vanguard Portfolio Management, LLC
2.05%
āļāļ·āđāļ āđ
78.70%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor
34.28%
Investment Advisor/Hedge Fund
23.69%
Research Firm
3.44%
Pension Fund
2.24%
Bank and Trust
1.61%
Sovereign Wealth Fund
1.36%
Insurance Company
1.24%
Hedge Fund
0.94%
Family Office
0.13%
āļāļ·āđāļ āđ
31.09%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 1 āđāļĄ.āļĒ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 1 āđāļĄ.āļĒ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2026Q1
4824
3.98B
69.87%
+29.48M
2025Q4
4757
3.86B
67.81%
-77.24M
2025Q3
4830
3.80B
66.84%
-140.11M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
State Street Investment Management (US)
300.45M
5.28%
+1.36M
+0.45%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
297.44M
5.23%
+3.29M
+1.12%
Dec 31, 2025
Geode Capital Management, L.L.C.
130.19M
2.29%
+1.18M
+0.92%
Dec 31, 2025
Fisher Investments
51.95M
0.91%
+2.66M
+5.41%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
73.53M
1.29%
-20.12M
-21.48%
Dec 31, 2025
State Farm Insurance Companies
57.74M
1.02%
+81.10K
+0.14%
Dec 31, 2025
BlackRock Asset Management Ireland Limited
54.65M
0.96%
+2.30M
+4.39%
Dec 31, 2025
MFS Investment Management
53.16M
0.93%
-1.80M
-3.28%
Dec 31, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļĢāđāļāļĩāđ 1 āļ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
VanEck Pharmaceutical ETF
10.43%
First Trust NASDAQ Pharmaceuticals ETF
7.73%
Franklin US Dividend Booster Index ETF
7.39%
First Trust Morningstar Dividend Leaders Index Fund
6.54%
WBI Power Factor High Dividend ETF
4.87%
Invesco Pharmaceuticals ETF
4.84%
Coastal Compass 100 ETF
4.8%
iShares U.S. Pharmaceuticals ETF
4.43%
Amplify Weight Loss Drug & Treatment ETF
4.14%
Roundhill GLP-1 & Weight Loss ETF
3.73%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
VanEck Pharmaceutical ETF
āļŠāļąāļāļŠāđāļ§āļ10.43%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ7.73%
Franklin US Dividend Booster Index ETF
āļŠāļąāļāļŠāđāļ§āļ7.39%
First Trust Morningstar Dividend Leaders Index Fund
āļŠāļąāļāļŠāđāļ§āļ6.54%
WBI Power Factor High Dividend ETF
āļŠāļąāļāļŠāđāļ§āļ4.87%
Invesco Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ4.84%
Coastal Compass 100 ETF
āļŠāļąāļāļŠāđāļ§āļ4.8%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ4.43%
Amplify Weight Loss Drug & Treatment ETF
āļŠāļąāļāļŠāđāļ§āļ4.14%
Roundhill GLP-1 & Weight Loss ETF
āļŠāļąāļāļŠāđāļ§āļ3.73%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
36.47B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
Apr 22, 2026
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 12, 2026 going ex on May 08, 2026
May 08, 2026
Jun 12, 2026
May 08, 2026
Dec 12, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 06, 2026 going ex on Jan 23, 2026
Jan 23, 2026
Mar 06, 2026
Jan 23, 2026
Oct 09, 2025
PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025
Nov 07, 2025
Dec 01, 2025
Nov 07, 2025
Jun 25, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025
Jul 25, 2025
Sep 02, 2025
Jul 25, 2025
Apr 23, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025
May 09, 2025
Jun 13, 2025
May 09, 2025
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
